HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC35D1
solute carrier family 35 member D1
Chromosome 1 Β· 1p31.3
NCBI Gene: 23169Ensembl: ENSG00000116704.9HGNC: HGNC:20800UniProt: Q9NTN3
22PubMed Papers
21Diseases
0Drugs
15Pathogenic Variants
FUNCTIONAL ROLE
Transporter
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
antiporter activitypyrimidine nucleotide-sugar transmembrane transportGolgi membranenucleotide-sugar transmembrane transportschneckenbecken dysplasianeurodegenerative diseasebenign neoplasm of adrenal glandEczematoid dermatitis
✦AI Summary

SLC35D1 is an endoplasmic reticulum (ER) nucleotide-sugar antiporter that exchanges UDP-sugars for nucleoside monophosphates or other nucleotide sugars 123. It transports multiple UDP-sugars including UDP-GlcNAc, UDP-GalNAc, and UDP-GlcA 412, which serve as sugar donors for ER glucosyltransferases synthesizing glycoproteins, glycolipids, and oligosaccharides 53. SLC35D1 plays a critical role in chondroitin sulfate biosynthesis, essential for cartilage extracellular matrix formation and skeletal development 5. The transporter may also couple UDP-GlcNAc or UDP-GalNAc efflux to UDP-GlcA influx, facilitating glucuronidation and excretion of endobiotics and xenobiotics 12. Loss-of-function mutations in SLC35D1 cause Schneckenbecken dysplasia, a severe autosomal recessive skeletal dysplasia characterized by limb shortening and facial structure abnormalities 53. Affected individuals exhibit defective chondroitin sulfate chains with shortened and sparse molecules 5. Hypomorphic alleles produce milder phenotypes with variable severity depending on residual transport activity 36. Additionally, GWAS fine-mapping identified SLC35D1 as a potential leprosy susceptibility gene, with disease-associated variants affecting mRNA expression and differential expression in leprosy patient skin tissues 7. The transporter's broad substrate specificity suggests roles beyond skeletal development in various ER glycosylation reactions 3.

Sources cited
1
SLC35D1 transports nucleotide sugars across the ER membrane in exchange for nucleoside monophosphates or other nucleotide sugars
PMID: 16965264
2
SLC35D1 transports UDP-sugars and may couple UDP-GlcNAc/UDP-GalNAc efflux to UDP-GlcA influx for glucuronidation
PMID: 17599910
3
SLC35D1 acts as a general UDP-sugar transporter with transport activity affected by missense mutations; hypomorphic alleles cause Schneckenbecken-like dysplasia
PMID: 31423530
4
SLC35D1 transports UDP-GlcNAc, UDP-GalNAc, and UDP-GlcA for glycosylation reactions
PMID: 11322953
5
SLC35D1 is critical for chondroitin sulfate synthesis in cartilage; Slc35d1-deficient mice develop lethal skeletal dysplasia with defective chondroitin sulfate chains; loss-of-function mutations cause Schneckenbecken dysplasia in humans
PMID: 17952091
6
GWAS identified SLC35D1 as a potential leprosy susceptibility gene; disease-associated variants affect SLC35D1 mRNA expression and are differentially expressed in leprosy patient skin tissues
PMID: 27712858
7
A novel SLC35D1 variant (p.Met134Thr) causes a milder phenotype of Schneckenbecken dysplasia with variable severity
PMID: 35934917
Disease Associationsβ“˜21
schneckenbecken dysplasiaOpen Targets
0.80Strong
neurodegenerative diseaseOpen Targets
0.39Weak
benign neoplasm of adrenal glandOpen Targets
0.26Weak
Eczematoid dermatitisOpen Targets
0.22Weak
genetic disorderOpen Targets
0.19Weak
connective tissue diseaseOpen Targets
0.17Weak
benign colon neoplasmOpen Targets
0.14Weak
autosomal recessive limb-girdle muscular dystrophy type 2HOpen Targets
0.12Weak
Abnormal thrombosisOpen Targets
0.10Weak
allergic diseaseOpen Targets
0.10Weak
respiratory system diseaseOpen Targets
0.09Suggestive
nephrotic syndromeOpen Targets
0.07Suggestive
psoriasisOpen Targets
0.06Suggestive
deep vein thrombosisOpen Targets
0.05Suggestive
hypertrophic cardiomyopathyOpen Targets
0.05Suggestive
ocular hypotensionOpen Targets
0.05Suggestive
atelosteogenesis type IIOpen Targets
0.05Suggestive
platyspondylic dysplasia, Torrance typeOpen Targets
0.05Suggestive
spondylometaphyseal dysplasia, Schmidt typeOpen Targets
0.05Suggestive
allergic rhinitisOpen Targets
0.05Suggestive
Schneckenbecken dysplasiaUniProt
Pathogenic Variants15
NM_015139.3(SLC35D1):c.932G>A (p.Trp311Ter)Likely pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2025β†’ Residue 311
NM_015139.3(SLC35D1):c.850dup (p.Thr284fs)Pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2025β†’ Residue 284
NM_015139.3(SLC35D1):c.479G>A (p.Trp160Ter)Pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2025β†’ Residue 160
NM_015139.3(SLC35D1):c.876+1G>ALikely pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2024
NM_015139.3(SLC35D1):c.637G>T (p.Glu213Ter)Likely pathogenic
SLC35D1-related disorder
β˜…β˜†β˜†β˜†2023β†’ Residue 213
NM_015139.3(SLC35D1):c.64_70del (p.Thr22fs)Pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2022β†’ Residue 22
NM_015139.3(SLC35D1):c.496_497del (p.Val166fs)Likely pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2021β†’ Residue 166
NM_015139.3(SLC35D1):c.464+1G>CLikely pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2021
NM_015139.3(SLC35D1):c.919T>A (p.Tyr307Asn)Likely pathogenic
Schneckenbecken dysplasia
β˜…β˜†β˜†β˜†2021β†’ Residue 307
NM_015139.3(SLC35D1):c.392+3A>GPathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2009
NM_015139.3(SLC35D1):c.533+730_637-1766delPathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2009
NM_015139.3(SLC35D1):c.319C>T (p.Arg107Ter)Pathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2009β†’ Residue 107
NM_015139.3(SLC35D1):c.193A>C (p.Thr65Pro)Pathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2009β†’ Residue 65
NM_015139.3(SLC35D1):c.125del (p.Lys42fs)Pathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2007β†’ Residue 42
NM_015139.3(SLC35D1):c.636+1G>TPathogenic
Schneckenbecken dysplasia
β˜†β˜†β˜†β˜†2007
View on ClinVar β†—
Related Genes
SLC35B1Protein interaction95%COQ4Protein interaction88%SLC35B2Protein interaction88%SLC35B3Protein interaction86%MAN2A2Protein interaction81%MAN2A1Protein interaction78%
Tissue Expression6 tissues
Liver
100%
Bone Marrow
29%
Ovary
17%
Lung
10%
Heart
9%
Brain
6%
Gene Interaction Network
Click a node to explore
SLC35D1SLC35B1COQ4SLC35B2SLC35B3MAN2A2MAN2A1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q9NTN3
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.98LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.69 [0.50–0.98]
RankingsWhere SLC35D1 stands among ~20K protein-coding genes
  • #13,741of 20,598
    Most Researched22
  • #2,487of 5,498
    Most Pathogenic Variants15
  • #9,366of 17,882
    Most Constrained (LOEUF)0.98
Genes detectedSLC35D1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human.
PMID: 17952091
Nat Med Β· 2007
1.00
2
Fine mapping of the GWAS loci identifies SLC35D1 and IL23R as potential risk genes for leprosy.
PMID: 27712858
J Dermatol Sci Β· 2016
0.90
3
A hypomorphic allele of SLC35D1 results in Schneckenbecken-like dysplasia.
PMID: 31423530
Hum Mol Genet Β· 2019
0.80
4
A novel SLC35D1 variant causing milder phenotype of Schneckenbecken dysplasia in a large pedigree.
PMID: 35934917
Am J Med Genet A Β· 2022
0.70
5
Whole Genome Sequencing Indicates Heterogeneity of Hyperostotic Disorders in Dogs.
PMID: 32033218
Genes (Basel) Β· 2020
0.60